AHA Video: Price unveils GRAVITAS results

TriMed Staff | | Cardiovascular Business | Interventional Cardiology
Click to play
AHA Video: Matthew J. Price, MD
GRAVITAS Principal Investigator
CHICAGO—Matthew J. Price, MD, sits down to discuss the much-anticipated results of the late-breaking GRAVITAS trial, along with the importance of platelet reactivity testing in real-life clinical practice to ensure more personalized therapy.

Price also touches upon the next steps of research, including whether phenotyping or genotyping patients who are candidates for an antiplatelet therapy is applicable.

TriMed Staff

Related Content

Surgery outperforms PCI in NSTEMI patients with multivessel CAD
Boston Scientific enters IVL arms race with acquisition worth up to $664M
FDA sees value in no-implant heart failure device
Radial secondary access during TAVR limits complications
Medtronic’s Harmony TPVR system gains CE mark approval
History made: Young child treated with new heart device for very first time

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.